Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab

Abstract The addition of pertuzumab (P) to trastuzumab (H) and neoadjuvant chemotherapy (NAC) has decreased the risk of distant recurrence in early stage HER2-positive breast cancer. The incidence of brain metastases (BM) in patients who achieved pathological complete response (pCR) versus those who...

Full description

Bibliographic Details
Main Authors: Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea V. Barrio, Rachna Malani, Ingo K. Mellinghoff, Adrienne Boire, Hannah Y. Wen, Edi Brogi, Andrew D. Seidman, Larry Norton, Mark E. Robson, Chau T. Dang
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00380-7

Internet

https://doi.org/10.1038/s41523-022-00380-7

Similar Items